ArticleESMO gastrointestinal oncology2025
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab.Journal of gastrointestinal cancer · 2026Article
- Article
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several nutritional and inflammatory indices can predict the efficacy of immune checkpoint inhibitors and the prognosis in various cancers. However, indices that are useful for patients with advanced gastric cancer (AGC) remain unclear. Materials and methods: This retrospective study was conducted at a single cancer center. Patients with AGC who received nivolumab as a third- or later-line treatment between June 2017 and May 2023 were selected. The association between nutritional and inflammatory indices and clinical outcomes was analyzed. Results: In total, 277 patients were analyzed. Multivariate analysis revealed that several indices were significantly associated with time to treatment failure (TTF) and overall survival (OS) after adjustment for clinicopathological factors. The modified Glasgow prognostic score (mGPS) and systemic immune-inflammation index (SII) were identified as the most promising indices. A combined score (CS) developed by summing the SII and mGPS was associated with a shorter TTF and OS in CS 1 or 2 than in CS 0 [TTF: hazard ratio (HR) 1.39, 95% confidence interval (CI) 1.04-1.87, Conclusion: CS may be useful for predicting treatment efficacy and prognosis in nivolumab-treated patients with AGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.